Pralatrexate
- Generic Name
- Pralatrexate
- Brand Names
- Folotyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N7O5
- CAS Number
- 146464-95-1
- Unique Ingredient Identifier
- A8Q8I19Q20
- Background
Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma . Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have a hi...
- Indication
Pralatrexate is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma.
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL), Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
- Associated Therapies
- -
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 11
- Registration Number
- NCT01114282
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 29
- Registration Number
- NCT00998946
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Owsley Brown Frazier Cancer Center, Louisville, Kentucky, United States
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 201
- Registration Number
- NCT00606502
- Locations
- 🇺🇸
Donald Berdeaux, Great Falls, Montana, United States
🇦🇷Instituto Medico Especializado Alexander Fleming, Buenos Aires, Cuidad De Buenos Aires, Argentina
🇦🇷Policlinica Privada - Instituto de Medicina Nuclear, Bahia Blanca, Provincia De Buenos Aires, Argentina
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00554827
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-12
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004238
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00024245
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00052442
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.